Cited 0 times in
Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강석민 | - |
dc.date.accessioned | 2024-05-30T07:02:48Z | - |
dc.date.available | 2024-05-30T07:02:48Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 0920-3206 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/199529 | - |
dc.description.abstract | Purpose Carvedilol demonstrated therapeutic benefits in patients with heart failure and reduced ejection fraction (HFrEF). However, it had a short half-life time mandating twice a day administration. We investigated whether slow-release carvedilol (carvedilol-SR) is non-inferior to standard immediate-release carvedilol (carvedilol-IR) in terms of clinical efficacy in patients with HFrEF. Methods We randomly assigned patients with HFrEF to receive carvedilol-SR once a day or carvedilol-IR twice a day. The primary endpoint was the change in N-terminal pro B-natriuretic peptide (NT-proBNP) level from baseline to 6 months after randomization. The secondary outcomes were proportion of patients with NT-proBNP increment > 10% from baseline, mortality rate, readmission rate, changes in blood pressure, quality of life, and drug compliance. Results A total of 272 patients were randomized and treated (median follow-up time, 173 days). In each group of patients taking carvedilol-SR and those taking carvedilol-IR, clinical characteristics were well balanced. No patient died during follow-up, and there was no significant difference in the change of NT-proBNP level between two groups (-107.4 [-440.2-70.3] pg/mL vs. -91.2 [-504.1-37.4] pg/mL, p = 0.101). Change of systolic and diastolic blood pressure, control rate and response rate of blood pressure, readmission rate, and drug compliance rate were also similar. For safety outcomes, the occurrence of adverse reactions did not differ between carvedilol-SR group and carvedilol-IR group. Conclusion Carvedilol-SR once a day was non-inferior to carvedilol-IR twice a day in patients with HFrEF. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Kluwer Academic For The International Society For Cardiovascular Pharmacotherapy | - |
dc.relation.isPartOf | CARDIOVASCULAR DRUGS AND THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Biomarkers | - |
dc.subject.MESH | Carvedilol / adverse effects | - |
dc.subject.MESH | Heart Failure* / diagnosis | - |
dc.subject.MESH | Heart Failure* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Natriuretic Peptide, Brain | - |
dc.subject.MESH | Peptide Fragments | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Quality of Life | - |
dc.subject.MESH | Stroke Volume | - |
dc.title | Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Chan Soon Park | - |
dc.contributor.googleauthor | Jin Joo Park | - |
dc.contributor.googleauthor | Hae-Young Lee | - |
dc.contributor.googleauthor | Seok-Min Kang | - |
dc.contributor.googleauthor | Byung-Su Yoo | - |
dc.contributor.googleauthor | Eun-Seok Jeon | - |
dc.contributor.googleauthor | Suk Keun Hong | - |
dc.contributor.googleauthor | Joon-Han Shin | - |
dc.contributor.googleauthor | Myung-A Kim | - |
dc.contributor.googleauthor | Dae-Gyun Park | - |
dc.contributor.googleauthor | Eung-Ju Kim | - |
dc.contributor.googleauthor | Soon-Jun Hong | - |
dc.contributor.googleauthor | Seok Yeon Kim | - |
dc.contributor.googleauthor | Jae-Joong Kim | - |
dc.contributor.googleauthor | Dong-Ju Choi | - |
dc.identifier.doi | 10.1007/s10557-021-07238-3 | - |
dc.contributor.localId | A00037 | - |
dc.relation.journalcode | J00461 | - |
dc.identifier.eissn | 1573-7241 | - |
dc.identifier.pmid | 35066737 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s10557-021-07238-3 | - |
dc.subject.keyword | Carvedilol | - |
dc.subject.keyword | Clinical efficacy | - |
dc.subject.keyword | Heart failure with reduced ejection fraction | - |
dc.subject.keyword | NT-proBNP | - |
dc.subject.keyword | Slow release | - |
dc.contributor.alternativeName | Kang, Seok Min | - |
dc.contributor.affiliatedAuthor | 강석민 | - |
dc.citation.volume | 37 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 529 | - |
dc.citation.endPage | 537 | - |
dc.identifier.bibliographicCitation | CARDIOVASCULAR DRUGS AND THERAPY, Vol.37(3) : 529-537, 2023-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.